relapsing refractory multiple myeloma market size
DelveInsight's "Relapsing Refractory Multiple Myeloma- Market Insights, Epidemiology and Market Forecast-2028" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Relapsing Refractory Multiple Myeloma in Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia).
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Relapsing Refractory Multiple Myeloma from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• Asia (China and Taiwan)
• Middle East (Saudi Arabia and UAE)
• Eastern Europe (Russia and Turkey)
• LATAM (Mexico, Brazil, Argentina and Columbia)
Study Period: 2017-2028
Relapsing Refractory Multiple Myeloma - Disease Understanding and Treatment Algorithm
Multiple Myeloma (MM) is the second most incident hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow. The mechanism of action of MM characterized by the unusual increase of monoclonal paraprotein leading to evidence of specific end-organ damage. The majority of patients with multiple myeloma (MM) will have an initial response to treatment with modern combination regimens. However, conventional therapy is not curative and most of these patients will ultimately progress. In addition, some patients will not respond to initial treatment (i.e., refractory disease). Relapsed or refractory MM is usually identified through routine monitoring with laboratory studies. The signs and symptoms of Multiple Myeloma include hypercalcemia, renal insufficiency, anemia, lytic bony lesions along with a monoclonal protein in the serum, increase in the number of clonal plasma cells in the bone marrow, etc.
The DelveInsight Relapsing Refractory Multiple Myeloma market report gives the thorough understanding of the Relapsing Refractory Multiple Myeloma by including details such as disease introduction, symptoms of multiple myeloma, molecular classification of Multiple Myeloma, stages of multiple myeloma, pathogenesis, pathophysiology, biomarkers for multiple myeloma, diagnosis and patient-related risk factors.
Relapsing Refractory Multiple Myeloma Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Relapsing Refractory Multiple Myeloma in 10 EM covering Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia) from 2017-2028 for the following aspects:
• Diagnosed Incident cases of Multiple Myeloma (MM)
• Gender-specific Diagnosed Incidence of Multiple Myeloma (MM)
• Diagnosed Incident Multiple Myeloma (MM) Population on Second Line of Treatment
• Diagnosed Incident Multiple Myeloma (MM) Population on Third Line (and above) of Treatment
• Total Diagnosed Incident RRMM cases
There are several potential research papers and studies evaluated in order to analyze the overall epidemiology trend in the emerging markets. Few are listed below:
Lu et al. conducted a study “Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis” with the aim to understand the clinical features and treatment outcome of Chinese patients with multiple myeloma (MM). As per the study, if the Japanese incidence of MM is applied to China, there would be an estimated 27,800 new cases (1.39 billion × 2 per 100,000) each year and a total of 200,000 cases in China. With the acceleration of the aging process in China, it is predicted that MM, with rapid growth in incidence, will become one of the more significant diseases that affect people's health in the country. It has also been reported that immigrants from Asia living in the USA have an increased incidence of MM compared with those living in Asia.
Hungria et al. suggest that Multiple Myeloma (MM) is a disorder characterized by abnormal clonal proliferation of plasmocytes in the bone marrow resulting in the production of monoclonal immunoglobulins associated with organic disorders. MM accounts for 1% of all neoplastic diseases and 13% of hematologic neoplasms as stated in “Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012.” In Brazil, there is no exact knowledge of the incidence of this disease.
Relapsing Refractory Multiple Myeloma Drug Chapters
This segment of the Relapsing Refractory Multiple Myeloma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
To meet the increasing demand for the treatment of Relapsing Refractory Multiple Myeloma, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of Relapsing Refractory Multiple Myeloma and awareness of the disease. The overall dynamics of Relapsing Refractory Multiple Myeloma market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Oncopeptides, Celgene/Bluebird Bio, Sanofi, Legend Biotech Biotech/Janssen Biotech, GlaxoSmithKline, Pharmacyclics and Karyopharm Therapeutics will significantly increase the market during the forecast period (2019-2028).
Relapsing Refractory Multiple Myeloma Market Outlook
Multiple Myeloma (MM) is a blood cancer affecting plasma cells. The malignant plasma cells show metastases aggravating the problem. In some cases, cancer returns after the treatment or after a period of remission. Most of the patients relapse at some point due to lack of specific cure. Adding worries to myeloma condition, some patients do not respond to the therapy (or sometimes respond to initial treatment, but not to the treatment following a relapse) thereby becoming refractory, and hence known as Relapsing Refractory Multiple Myeloma (RRMM).
The market holds a diverse range of therapeutic alternatives for treatment, including Proteasome Inhibitors, Immunomodulating Agents, Histone Deacetylase (HDAC) inhibitors, Monoclonal Antibodies, Chemotherapy, Corticosteroids, and Nuclear export inhibitors in different lines of treatment. The treatment pattern lays more focus on second line of therapy and above for RRMM. Proteasome Inhibitors (PIs) forms a widely used class for treatment, including Bortezomib (Velcade), Carfilzomib (Kyprolis), and Ixazomib (Ninlaro). Proteasome inhibitors work by inhibiting enzyme complexes (proteasomes) in cells from breaking down proteins important for controlling cell division. PIs affect tumor cells more than normal cells but also accompanies few side effects. The next in the list is Immunomodulators (IMiDs), including Thalidomide (Thalomid), Lenalidomide (Revlimid), and Pomalidomide (Pomalyst/Imnovid). IMiDs possess pleiotropic anti-myeloma properties, including immune-modulation, anti-angiogenic, anti-inflammatory, and anti-proliferative effects. IMiDs can increase the blood-clotting risk, thereby often given along with aspirin or a blood thinner. The treatment regime also includes Histone Deactylase (HDAC) Inhibitors affecting active genes or by interacting with proteins in chromosomes called histones. Panobinostat (Farydak) is an HDAC inhibitor used to treat patients who have already been treated with bortezomib and an immunomodulating agent. Monoclonal Antibodies have gained great popularity for the treatment of myeloma. Antibodies are proteins made by the body's immune system to help fight infections. Man-made versions (monoclonal antibodies), can be designed to attack a specific target, such as proteins on the surface of myeloma cells. mAbs used for the treatment of RRMM include Daratumumab (Darzalex) and Elotuzumab (Empliciti). The other treatment alternatives comprise Chemotherapy drugs and Corticosteroids.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Relapsing Refractory Multiple Myeloma in 10 EM is expected to change from 2019-2028.
Relapsing Refractory Multiple Myeloma Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Expected launch of therapies for Relapsing Refractory Multiple Myeloma such as Melflufen (Oncopeptides), Idecabtagene vicleucel (Celgene/Bluebird), Isatuximab (Sanofi), JNJ-68284528 (Legend Biotech Biotech/Janssen Biotech), GSK2857916 (GlaxoSmithKline), Ibrutinib (Pharmacyclics) and Xpovio (Karyopharm Therapeutics) targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Relapsing Refractory Multiple Myeloma market. Although approved only in the United States, the drug has not been launched in the emerging markets, therefore considered as an emerging therapy in this region.
Relapsing Refractory Multiple Myeloma Report Insights
• Patient Population
• Therapeutic Approaches
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Relapsing Refractory Multiple Myeloma Report Key Strengths
• 10 Year Forecast
• 10 EM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition
Relapsing Refractory Multiple Myeloma Report Assessment
• Current Treatment Practices
• Unmet Needs
• Market Attractiveness
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Relapsing Refractory Multiple Myeloma market
• Organize sales and marketing efforts by identifying the best opportunities for Relapsing Refractory Multiple Myeloma market
• To understand the future market competition in the Relapsing Refractory Multiple Myeloma market.
